Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …

Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response
and different cytokine-blocking biologic agents were explored to improve outcomes …

Objective The aim of this study was to evaluate the efficacy of anakinra in patients who were
admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. Methods A …

Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …

Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …

Objective To report the clinical experience with anakinra in preventing mechanical
ventilation in patients with coronavirus disease 2019 (COVID‐19), symptoms of cytokine …

Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …